To determine if increase in promoter activity facilitated by ER antagonism (shown above) translates to increased expression of the encoded protein, ER+PR+ T47D breast cancer cells were treated with Tamoxifen or Fulvestrant at 0.1 mM and 0.1 μm respectively (optimal doses as determined above). The gene discussed is PGR; the disease is breast cancer.